Overexpression of hBD3 inhibits cell proliferation, cell cycle, and migration in colon cancer cells

doi:10.5246/jcps.2023.04.022

Abstract

Abstract:

In the present study, we investigated the effects of human β-defensin-3 (hBD3) on the proliferation, cell cycle, and migration of HCT116 cells. The eukaryotic expression vector pcDNA3.1-hBD3 was transfected into human colon cancer HCT116 cells. The transfection efficiency was detected by qPCR and Western blotting analysis. The expressions of β-catenin, E-cadherin, and N-cadherin at the protein level were assessed by Western blotting analysis. Single-channel Hoechst33342 was used to detect the number of nuclei and calculate the proportion of proliferating cells. The cell cycle was detected by flow cytometry. The migration ability of HCT116 cells was detected by wound-healing and transwell assays. The results showed that the ability of migration and proliferation was inhibited, and the cell cycle G2/M phase was blocked. The expressions of β-catenin and N-cadherin at the protein level in HCT116-hBD3 cells were lower than those in HCT116 and HCT116-Blank cells, while the expression of E-cadherin at the protein level in HCT116-hBD3 cells was higher than that in HCT116 and HCT116-Blank cells. These findings suggested that hBD3 could regulate the migration and proliferation of HCT116 cells by regulating the Wnt/β-catenin signaling pathway.

Key words: Human β defensin-3, Proliferation, Migration, Colon cancer, HCT116 cells, Wnt/β-catenin signaling pathway, Cell cycle

Supporting:

Yancong Zhao, Huiyuan Gong, Jinghua Li. Overexpression of hBD3 inhibits cell proliferation, cell cycle, and migration in colon cancer cells[J]. Journal of Chinese Pharmaceutical Sciences, 2023, 32(4): 250-259.

Figures/Tables 6

References 15

[1]	It’s from the International Agency for Research on Cancer (IARC). The latest global cancer statistics were released in December 2020 (https://www.iarc.who.int/wp-content/uploads/2020/12/pr292_E.Pdf).
[2]	Berian, J.R.; Benson, A.B. 3rd.; Nelson, H. Young age and aggressive treatment in colon cancer. J. Am. Med. Assoc. 2015, 314, 613–614.
[3]	Siegel, R.L.; Miller, K.D.; Goding Sauer, A.; Fedewa, S.A.; Butterly, L.F.; Anderson, J.C.; Cercek, A.; Smith, R.A.; Jemal, A. Colorectal cancer statistics, 2020. CA Cancer J. Clin. 2020, 70, 145–164.
[4]	Liu, S.; Zheng, R.; Zhang, M.; Zhang, S.; Sun, X.; Chen, W. Incidence and mortality of colorectal cancer in China, 2011. Chin. J. Cancer Res. 2015, 27, 22–28.
[5]	Gerovska, D.; García-Gallastegi, P.; Descarpentrie, J.; Crende, O.; Casado-Andrés, M.; Martín, A.; Eguia, J.; Khatib, A.M.; Araúzo-Bravo, M.J.; Badiola, I. Proprotein convertases blockage up-regulates specifically metallothioneins coding genes in human colon cancer stem cells. Biochim. Biophys. Acta BBA Mol. Cell Res. 2021, 1868, 118912.
[6]	Ma, W.W.; Yu, S.W. IC5, a dithiocarbamate derivative, inhibits colon cancer cell proliferation in vitro and colitis-associated colorectal carcinogenesis in vivo. J. Chin. Pharm. Sci. 2014, 23, 610–616.
[7]	Malki, A.; ElRuz, R.A.; Gupta, I.; Allouch, A.; Vranic, S.; Al Moustafa, A.E. Molecular mechanisms of colon cancer progression and metastasis: recent insights and advancements. Int. J. Mol. Sci. 2020, 22, E130.
[8]	Jahanafrooz, Z.; Mosafer, J.; Akbari, M.; Hashemzaei, M.; Mokhtarzadeh, A.; Baradaran, B. Colon cancer therapy by focusing on colon cancer stem cells and their tumor microenvironment. J. Cell Physiol. 2020, 235, 4153–4166.
[9]	Zhang, H.; Men, K.; Pan, C.; Gao, Y.; Li, J.; Lei, S.; Zhu, G.; Li, R.; Wei, Y.; Duan, X. Treatment of colon cancer by degradable rrPPC nano-conjugates delivered STAT3 siRNA. Int. J. Nanomed. 2020, 15, 9875–9890.
[10]	Wang, K.; Wang, J.H.; Baskaran, H.; Wang, R.; Jurevic, R. Effect of human beta-defensin-3 on head and neck cancer cell migration using micro-fabricated cell Islands. Head Neck Oncol. 2012, 4, 41.
[11]	Uraki, S.; Sugimoto, K.; Shiraki, K.; Tameda, M.; Inagaki, Y.; Ogura, S.; Kasai, C.K.; Nojiri, K.; Yoneda, M.; Yamamoto, N.; Takei, Y.; Nobori, T.; Ito, M. Human β-defensin-3 inhibits migration of colon cancer cells via downregulation of metastasis-associated 1 family, member 2 expression. Int. J. Oncol. 2014, 45, 1059–1064.
[12]	Reddy, K.V.R. Antimicrobial peptides: premises and promises. Int. J. Antimicrob. Agents. 2004, 24, 536–547.
[13]	Brogden, K.A.Jr. Antimicrobial peptides in animals and their role in host defences. Int. J. Antimicrob. Agents. 2003, 22, 465–478.
[14]	Wiechula, B.E.; Tustanowski, J.P.; Martirosian, G. [Antimicrobial peptides]. Wiad Lek. 2006, 59, 542–547.
[15]	Han, Z.; Huang, X. D.; Liu, M.; Zhu, Q.X.; Tan, J.; Liu, W.J.; Chen, W.; Zou, Y.L.; Cai, Y.S.; Huang, S.S.; Tian, X. Noscapine inhibits migration of colon cancer SW480 cells by down-regulating Wnt3a/β-catenin signal pathway and cadherin 17. Chin. J. Cancer Biother. 2019, 26, 1089–1094.